MYC and aggressive B-cell lymphomas
- PMID: 21490439
- DOI: 10.1097/PAP.0b013e3182169948
MYC and aggressive B-cell lymphomas
Abstract
Rearrangement of the proto-oncogene MYC leads to MYC protein deregulation and is an important driver of oncogenic transformation. MYC rearrangement is a recurring genetic abnormality in several aggressive B-cell lymphomas including: Burkitt lymphoma, diffuse large B-cell lymphoma; B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma; rare de novo acute lymphoblastic lymphoma/leukemia, transformed follicular lymphoma, and plasmablastic lymphoma. Important distinctions in the role of MYC in these tumors likely reflect whether it is a primary or secondary genetic event. The presence of a MYC rearrangement in these diseases has diagnostic and prognostic implications and it is important for the practicing anatomic pathologist to be familiar with these issues when diagnosing aggressive B-cell lymphomas. This review provides a brief overview of MYC biology; shows the clinical and pathologic features of the aggressive B-cell lymphomas that harbor recurrent MYC rearrangements; explores the diagnostic and clinical implications of MYC rearrangements in these diseases; and outlines the techniques available to the anatomic pathologist to detect MYC deregulation.
Similar articles
-
Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.Cancer. 2012 Mar 15;118(6):1566-73. doi: 10.1002/cncr.26433. Epub 2011 Aug 31. Cancer. 2012. PMID: 21882178
-
Altered subcellular localization of c-Myc protein identifies aggressive B-cell lymphomas harboring a c-MYC translocation.Am J Surg Pathol. 2010 Jun;34(6):882-91. doi: 10.1097/PAS.0b013e3181db83af. Am J Surg Pathol. 2010. PMID: 20442643
-
B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.Am J Surg Pathol. 2010 Mar;34(3):327-40. doi: 10.1097/PAS.0b013e3181cd3aeb. Am J Surg Pathol. 2010. PMID: 20118770 Free PMC article.
-
The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective.J Clin Oncol. 2011 May 10;29(14):1835-43. doi: 10.1200/JCO.2010.32.8385. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21482997 Review.
-
Comprehensive Assessment and Classification of High-Grade B-cell Lymphomas.Surg Pathol Clin. 2016 Mar;9(1):41-54. doi: 10.1016/j.path.2015.09.008. Surg Pathol Clin. 2016. PMID: 26940267 Review.
Cited by
-
How lactate affects immune strategies in lymphoma.Front Mol Biosci. 2024 Oct 11;11:1480884. doi: 10.3389/fmolb.2024.1480884. eCollection 2024. Front Mol Biosci. 2024. PMID: 39464313 Free PMC article. Review.
-
Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma.Oncotarget. 2016 Jun 21;7(25):38122-38132. doi: 10.18632/oncotarget.9473. Oncotarget. 2016. PMID: 27203548 Free PMC article.
-
MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Haematologica. 2013 Oct;98(10):1554-62. doi: 10.3324/haematol.2013.086173. Epub 2013 May 28. Haematologica. 2013. PMID: 23716551 Free PMC article.
-
PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.J Clin Invest. 2018 Dec 3;128(12):5517-5530. doi: 10.1172/JCI122533. Epub 2018 Nov 5. J Clin Invest. 2018. PMID: 30260324 Free PMC article.
-
circLMTK2 acts as a sponge of miR-150-5p and promotes proliferation and metastasis in gastric cancer.Mol Cancer. 2019 Nov 14;18(1):162. doi: 10.1186/s12943-019-1081-4. Mol Cancer. 2019. PMID: 31722712 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources